AR096645A1 - COMBINATIONS OF BENZOPIRANO COMPOUNDS, COMPOSITIONS AND USES OF THESE - Google Patents

COMBINATIONS OF BENZOPIRANO COMPOUNDS, COMPOSITIONS AND USES OF THESE

Info

Publication number
AR096645A1
AR096645A1 ARP140102308A ARP140102308A AR096645A1 AR 096645 A1 AR096645 A1 AR 096645A1 AR P140102308 A ARP140102308 A AR P140102308A AR P140102308 A ARP140102308 A AR P140102308A AR 096645 A1 AR096645 A1 AR 096645A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
orc1
inhibitor
administration
Prior art date
Application number
ARP140102308A
Other languages
Spanish (es)
Original Assignee
Olema Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olema Pharmaceuticals Inc filed Critical Olema Pharmaceuticals Inc
Publication of AR096645A1 publication Critical patent/AR096645A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un método para tratar un trastorno modulado, mediado o afectado por el receptor estrogénico en un sujeto, caracterizado porque comprende la administración al sujeto de un compuesto, que es seleccionado del grupo de fórmulas (1), en donde R¹ y R² son independientemente: (i) OH u OR⁹, (ii) en donde R⁹ se selecciona independientemente de H, halógeno (Cl, Br, I o F), aminoácido natural o no natural (ligado mediante OC(O)- o C(O)O- (un éster) o amino (mediante -C(O)-N- o -N-C(O)- (una ligadura de amida)), R¹⁰, -OR¹⁰ o -SR¹⁰ en donde R¹⁰ es -C(=O)RC¹, -C(=O)ORC¹, -C(=O)SRC¹, -C(=O)N(RC¹)₂; o polietilenglicol, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, carbociclilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, arilo sustituido o no sustituido o heteroarilo sustituido o no sustituido; -S(=O)₂RC¹, -S(=O)₂ORC¹, -S(=O)RC¹,-S(=O)ORC¹, -P(=O)₂RC¹, -P(=O)₂ORC¹, -P(=O)(ORC¹)₂, -P(=O)(RC¹)₂ o -P(Rᶜ¹)(ORC¹); u oxígeno unido a un grupo protector de oxígeno (para producir OH en la administración), azufre unido a un grupo protector de azufre (para producir SH o un disulfuro en la administración) o nitrógeno unido a un grupo protector de nitrógeno (para producir -NH- en la administración) y RC¹ se puede seleccionar independientemente de hidrógeno, polietilenglicol, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, carbociclilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, arilo sustituido o no sustituido o heteroarilo sustituido o no sustituido, o dos grupos RC¹ que se unen para formar un anillo heterocíclico sustituido o no sustituido; o una sal aceptable desde el punto de vista farmacéutico, un solvato, un hidrato, un profármaco, un estereoisómero, un tautómero o un óxido N de aquel, en combinación con un agente seleccionado del grupo que consiste en un inhibidor de mTOR, un inhibidor de CDK 4/6, un inhibidor de la quinasa PI3, un taxano, un antimetabolito y un antibiótico antineoplásico. Reivindicación 15: El método de acuerdo con la reivindicación 14, caracterizado porque el inhibidor de CDK 4/6 es PD-0332991, LY2835219 o LEE011. Reivindicación 20: El método de acuerdo con la reivindicación 18, caracterizado porque el inhibidor de mTOR es rapamycin, everolimus, temsirolimus, AP23573, AZD8055, WYE-354, WYE-600, WYE-687 o Pp121. Reivindicación 22: El método de acuerdo con la reivindicación 21, caracterizado porque el inhibidor de la quinasa PI3 es BKM-120, XL-147, RG-7321, CH-5132799 y BAY-80-6946. Reivindicación 25: El método de acuerdo con la reivindicación 24, caracterizado porque el taxano es paclitaxel o docetaxel. Reivindicación 27: El método de acuerdo con la reivindicación 26, caracterizado porque el antimetabolito es 5-flúorouracilo. Reivindicación 29: El método de acuerdo con la reivindicación 28, caracterizado porque el antibiótico antineoplásico es doxorubicina.Claim 1: A method for treating a disorder modulated, mediated or affected by the estrogenic receptor in a subject, characterized in that it comprises administration to the subject of a compound, which is selected from the group of formulas (1), wherein R¹ and R² are independently: (i) OH or OR⁹, (ii) wherein R⁹ is independently selected from H, halogen (Cl, Br, I or F), natural or unnatural amino acid (linked by OC (O) - or C (O) O- (an ester) or amino (by -C (O) -N- or -NC (O) - (an amide ligation)), R¹⁰, -OR¹⁰ or -SR¹⁰ where R¹⁰ is -C (= O) RC¹, -C (= O) ORC¹, -C (= O) SRC¹, -C (= O) N (RC¹) ₂; or polyethylene glycol, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl , substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; -S (= O) ₂RC¹, -S (= O) ₂ORC¹, -S (= O) RC¹, - S (= O) ORC¹, -P (= O) ₂RC¹, -P (= O) ₂ORC¹, -P (= O) (ORC¹) ₂, -P (= O) (RC¹) ₂ or -P (Rᶜ¹) (ORC¹); or oxygen attached to an oxygen protecting group (to produce OH in administration), sulfur attached to a sulfur protecting group (to produce SH or a disulfide in administration) or nitrogen attached to a nitrogen protecting group (to produce - NH- in the administration) and RC¹ can be independently selected from hydrogen, polyethylene glycol, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted aryl or unsubstituted or substituted or unsubstituted heteroaryl, or two RC¹ groups that join to form a substituted or unsubstituted heterocyclic ring; or a pharmaceutically acceptable salt, a solvate, a hydrate, a prodrug, a stereoisomer, a tautomer or an N oxide thereof, in combination with an agent selected from the group consisting of an mTOR inhibitor, an inhibitor of CDK 4/6, a PI3 kinase inhibitor, a taxane, an antimetabolite and an antineoplastic antibiotic. Claim 15: The method according to claim 14, characterized in that the CDK 4/6 inhibitor is PD-0332991, LY2835219 or LEE011. Claim 20: The method according to claim 18, characterized in that the mTOR inhibitor is rapamycin, everolimus, temsirolimus, AP23573, AZD8055, WYE-354, WYE-600, WYE-687 or Pp121. Claim 22: The method according to claim 21, characterized in that the PI3 kinase inhibitor is BKM-120, XL-147, RG-7321, CH-5132799 and BAY-80-6946. Claim 25: The method according to claim 24, characterized in that the taxane is paclitaxel or docetaxel. Claim 27: The method according to claim 26, characterized in that the antimetabolite is 5-fluorouracil. Claim 29: The method according to claim 28, characterized in that the antineoplastic antibiotic is doxorubicin.

ARP140102308A 2013-06-19 2014-06-18 COMBINATIONS OF BENZOPIRANO COMPOUNDS, COMPOSITIONS AND USES OF THESE AR096645A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361837130P 2013-06-19 2013-06-19

Publications (1)

Publication Number Publication Date
AR096645A1 true AR096645A1 (en) 2016-01-20

Family

ID=51022942

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102308A AR096645A1 (en) 2013-06-19 2014-06-18 COMBINATIONS OF BENZOPIRANO COMPOUNDS, COMPOSITIONS AND USES OF THESE

Country Status (4)

Country Link
JP (1) JP2015003909A (en)
AR (1) AR096645A1 (en)
TW (1) TW201511755A (en)
WO (1) WO2014203129A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39741A (en) * 2014-03-13 2017-01-18 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
DK3122426T3 (en) 2014-03-28 2023-04-03 Univ Duke Treatment of breast cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CN104529904B (en) * 2015-01-09 2016-08-31 苏州明锐医药科技有限公司 The preparation method of Bo Maxini
AR104068A1 (en) * 2015-03-26 2017-06-21 Hoffmann La Roche COMBINATIONS OF A 3-KINASE PHOSFOINOSYTIDE INHIBITOR COMPOSITE AND A CDK4 / 6 INHIBITOR COMPOUND FOR CANCER TREATMENT
MX2017013802A (en) 2015-04-29 2018-08-15 Radius Pharmaceuticals Inc Methods of treating cancer.
CA2995036A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
KR20180071274A (en) 2015-10-01 2018-06-27 올레마 파마슈티컬스 인코포레이티드 Tetrahydro-1H-pyrido [3,4-b] indole anti estrogen drug
LT3386500T (en) 2015-12-09 2022-12-27 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulators
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3454856A4 (en) 2016-05-10 2019-12-25 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
AU2017290748A1 (en) 2016-07-01 2019-01-17 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
MX2019007748A (en) * 2017-01-05 2019-09-09 Radius Pharmaceuticals Inc Polymorphic forms of rad1901-2hcl.
TWI823845B (en) 2017-01-06 2023-12-01 美商G1治療公司 Combination therapy for the treatment of cancer
EP4119552A1 (en) 2017-02-08 2023-01-18 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
AU2018217809A1 (en) 2017-02-10 2019-08-22 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
NZ759691A (en) 2017-06-29 2023-05-26 G1 Therapeutics Inc Morphic forms of git38 and methods of manufacture thereof
KR20200086278A (en) 2017-10-18 2020-07-16 노파르티스 아게 Compositions and methods for selective proteolysis
JP2021503448A (en) * 2017-11-16 2021-02-12 ノバルティス アーゲー Pharmaceutical combination containing LSZ102 and ribociclib
IT201800004082A1 (en) * 2018-03-29 2019-09-29 Berlin Chemie Ag ANTI-CANCER PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
WO2022199656A1 (en) * 2021-03-24 2022-09-29 贝达药业股份有限公司 Pharmaceutical combination, kit containing same, and use thereof
CN113045546A (en) * 2021-03-25 2021-06-29 浙江天宇药业股份有限公司 Azolidinib impurity, preparation method and application thereof
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
WO2024097989A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein degraders
WO2024097980A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668222A (en) 1969-05-14 1972-06-06 Sandoz Ltd 11-desacetoxy-wortmannin
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5254568A (en) 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5504103A (en) 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
CA2133815A1 (en) 1993-10-12 1995-04-13 Jeffrey Alan Dodge Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
US6413773B1 (en) 1998-06-01 2002-07-02 The Regents Of The University Of California Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6667340B1 (en) 1998-06-26 2003-12-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibitors of phosphatidyl myo-inositol cycle
US6262270B1 (en) 1998-08-14 2001-07-17 Schering Corporation Enantioselective synthesis
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
CN1400904A (en) 2000-01-28 2003-03-05 恩多研究公司 Selective estrogen receptor modulators in combination with estrogens
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
KR20060111716A (en) 2002-01-22 2006-10-27 워너-램버트 캄파니 엘엘씨 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
WO2004091488A2 (en) 2003-04-14 2004-10-28 Merck & Co., Inc. Estrogen receptor modulators
US20040259926A1 (en) 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
BRPI0410913A (en) 2003-06-05 2006-06-27 Warner Lambert Co cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents
EP1648889B1 (en) 2003-07-11 2008-10-29 Warner-Lambert Company LLC Isethionate salt of a selective cdk4 inhibitor
EP2046799B1 (en) 2006-04-26 2017-07-19 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
RU2009108006A (en) 2006-09-08 2010-10-20 Пфайзер Продактс Инк. (Us) SYNTHESIS OF 2- (PYRIDIN-2-ILAMINO) -PYRIDO [2, 3-D] PYRIMIDIN-7-ONES
KR101507182B1 (en) 2006-12-07 2015-03-30 제넨테크, 인크. Phosphoinositide 3-kinase inhibitor compounds and methods of use
NZ578162A (en) 2006-12-07 2011-12-22 Genentech Inc Phosphoinositide 3-kinase inhibitor compounds and methods of use
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
CA2857061A1 (en) 2011-12-16 2013-06-20 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof

Also Published As

Publication number Publication date
WO2014203129A1 (en) 2014-12-24
TW201511755A (en) 2015-04-01
JP2015003909A (en) 2015-01-08

Similar Documents

Publication Publication Date Title
AR096645A1 (en) COMBINATIONS OF BENZOPIRANO COMPOUNDS, COMPOSITIONS AND USES OF THESE
CY1123627T1 (en) DIHYDROIMIDAZOPYZINONE DERIVATIVES USEFUL IN THE THERAPEUTIC TREATMENT OF CANCER
CY1124239T1 (en) AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
CY1121699T1 (en) TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS
PE20200008A1 (en) ISOQUINOLINS AS INHIBITORS OF HPK1
DOP2018000187A (en) DERIVATIVES OF PIRAZOLO [1,5-A] PIRAZIN-4-ILO
PH12018502227A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
TR201802944T4 (en) DERIVATIVES OF AZAINDAZOL OR DIAZAINDAZOL
PE20220567A1 (en) NEW PIPERIDINIL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR128748A2 (en) SUBSTITUTED AMINOPURINE COMPOUNDS, THEIR COMPOSITIONS AND TREATMENT METHODS WITH THEM
BR112014019478A2 (en) a pharmaceutically acceptable salt or compound thereof, pharmaceutical composition, use of a pharmaceutically acceptable salt or compound thereof, sodium channel inhibitor formulation, methods for treating and / or preventing pain and disease.
CO6440596A2 (en) 3 KINASE PHOSFOINOSITI INHIBITORS AND / OR RAPAMYCIN MAMMAL OBJECTIVE
TN2016000090A1 (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors.
AR063096A1 (en) PIRAZOLOPIRIMIDINAS AS INHIBITORS OF CYCLINE-DEPENDENT KINASE
UY37459A (en) LIPOSOMAL FORMULATION
PE20181519A1 (en) SUBSTITUTE BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION
PE20212303A1 (en) AZA-HETEROBYCYCLIC MAT2A INHIBITORS AND METHODS OF USE IN THE TREATMENT OF CANCER
TN2019000170A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
DOP2012000053A (en) DERIVATIVES OF (UNCLE) MORPHOLINE AS MODULATORS OF S1P
PE20181017A1 (en) HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS
AR099874A1 (en) CHROMENE AND 1,1A, 2,7B-TETRAHYDROCICLOPROPA [C] CHROME PIRIDOPIRAZINADIONAS AS MODULATORS OF g-SECRETASE
CR20190236A (en) Therapeutic compounds and methods of use thereof
CY1124346T1 (en) CHROMANE, ISOCHROMANE, AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-APNHTIKOI ALLOSTERIC MODULATORS, THEIR COMPOSITIONS, AND USE THEREOF
CY1122018T1 (en) 6-MORPHOLINYL-2-PYRAZOLYL-9H-PURINE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS
PH12017502254B1 (en) Pyrazole derivative or pharmaceutically acceptable salt thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure